Enpatoran not checked

EMD Serono Research & Development Institute, Inc. · M5049

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
4 active
12 in total · 7 in the EU
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“Participants will receive a dose of Enpatoran orally twice daily from Day 1 to Day 168.”In the company’s words, NCT07332481 on ClinicalTrials.gov
Tested for
Systemic Lupus Erythematosus (SLE) (2 trials), Cutaneous Lupus Erythematosus (CLE) (2 trials), Systematic Lupus Erythematosus, Cutaneous Lupus Erythematosus, Systemic Lupus Erythematosus
Main trialPhase 3
“The purpose of this global, multicenter, Phase 3 study is to evaluate the efficacy and safety of enpatoran over 24 weeks in participants with active cutaneous manifestations of lupus erythematosus with or without systemic disease. Study details include: Study Duration: Up to 35 weeks. Treatment Duration: 24 weeks. Visit Frequency: every 4 weeks, with the exception of the Week 2 televisit. Study Intervention Name: Enpatoran, Placebo. Intervention Form: Film-coated tablet.”In the company’s words, NCT07332481 on ClinicalTrials.gov
Other names
M5049

Other drugs for Systemic Lupus Erythematosus (SLE)

All 131 drugs for Systemic Lupus Erythematosus (SLE)

Coming up4

Changes1

Last 90 days

Trials12

TrialPhaseCompletesWhat it tests
Phase 3Recruiting 24 May 2029 A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease
Phase 3Recruiting 25 May 2029 A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)
Phase 3Recruiting 1 Sep 2031 A Long-Term Extension (LTE) Study Of Enpatoran In Cutaneous Manifestations Of Lupus With Or Without Systemic Disease [Elowen-LTE]
Phase 2Active, not recruiting 12 Aug 2028 The Willow LTE Study With M5049 in Participants With SCLE, DLE and/or SLE (WILLOW LTE)
Phase 2Completed 16 Aug 2021 Study of M5049 in Participants With COVID-19 Pneumonia (ANEMONE)
Phase 2Completed 20 Nov 2024 The WILLOW Study With M5049 in SLE and CLE (SCLE and/or DLE) (WILLOW)
Phase 2Terminated 25 Jun 2025 Study of M5049 in DM and PM Participants (NEPTUNIA)
Phase 1Completed 23 Nov 2021 Study of M5049 in Healthy Japanese and Caucasian Participants
Phase 1Completed 24 Dec 2021 Enpatoran Human Mass Balance and Absolute Bioavailability Study
Phase 1Completed 19 Dec 2023 Study of M5049 in CLE and SLE Participants
Phase 1Completed 2 Dec 2024 A TQT Study to Investigate the Effect of Enpatoran on Cardiac Repolarization in Healthy Participants
Phase 1Completed 13 Apr 2026 Effect of Renal Impairment on Enpatoran Pharmacokinetics
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Enpatoran

Following is part of Solo: you see every change to Enpatoran the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in